AHA 2019: Conservative Approach Works As Well As Intervention For Stable Coronary Disease In ISCHEMIA Trial
Medtech-industry analysts predict the long-awaited trial results will have minimal impact on clinical practice or sales of coronary stents.
The long-awaited results of the ISCHEMIA trial showed that patients with asymptomatic stable coronary disease get no apparent benefit from coronary intervention compared to a more conservative strategy with optimal medical management.
You may also be interested in...
R&D Roundup, November 2019: LimFlow Starts Pivotal Trial Of Peripheral Shunt; Conservative Coronary Treatment Matches Intervention In Trial
An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.
EuroPCR 2018: Several Studies Add Insight To Best Approach To Stable Coronary Disease, Utility Of FFR
New clinical data presented at the EuroPCR conference in Paris, including new data from ORBITA, suggest that fractional flow reserve/ instant wave-free ratio-guided percutaneous coronary intervention may produce better long-term outcomes than PCI guided by angiography in terms of mortality, restenosis and stent thrombosis.
Although most patients undergoing diagnostic coronary catheterization before noncardiac surgery do not have symptoms of coronary disease, about half of these patients are referred for revascularization despite the lack of evidence showing a benefit of revascularization in these patients according to data from a large national registry.